Cagrilintide
Cagrilintide is a long-acting, lipidated amylin analogue. It is a different reference identity from the GLP-1 analogue semaglutide, even when the two are studied together.
Reviewed September 2026
- Residues
- 37. verified: 37 main-chain residues. The gamma-glutamyl lipidation spacer is excluded from this chain count but included in the full molecular mass.
- Average mass
- 4,409 Da. verified: Reference form: Cagrilintide reference amylin analogue: 37-residue main chain, Cys2–Cys7 disulfide, C-terminal prolinamide and N-terminal C20 diacid through gamma-glutamyl spacer. Not its hydrochloride salt.; formula C194H312N54O59S2. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
- pI
- Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.
Reference details
| Residues | 37 |
|---|---|
| Average mass | 4,409 Da |
| pI | Not established |
| Research area | Metabolic |
|---|
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Cagrilintide reference amylin analogue: 37-residue main chain, Cys2–Cys7 disulfide, C-terminal prolinamide and N-terminal C20 diacid through gamma-glutamyl spacer. Not its hydrochloride salt. Reference only, not a sold-lot measurement.
- Residues: 37 (verified). 37 main-chain residues. The gamma-glutamyl lipidation spacer is excluded from this chain count but included in the full molecular mass. Residues source 1 Residues source 2 Residues source 3
- Average mass: 4,409 Da (verified). Reference form: Cagrilintide reference amylin analogue: 37-residue main chain, Cys2–Cys7 disulfide, C-terminal prolinamide and N-terminal C20 diacid through gamma-glutamyl spacer. Not its hydrochloride salt.; formula C194H312N54O59S2. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
- pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1
Reference scope and linked records
Reference type: Modified peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: Cagrilintide. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- Development of Cagrilintide, a Long-Acting Amylin Analogue. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About Cagrilintide
Identity and context
The development paper describes the challenge of amylin aggregation and the structure-activity work used to select a stable lipidated analogue. The lipid modification and analogue chemistry are essential to the identity; native amylin is not an adequate substitute in a structure record.
Reference classification
Modified peptide. The linked catalogue product is Cagrilintide. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Confirm the full modified peptide structure and analytical form. For a mixture, obtain the amount of cagrilintide separately from semaglutide rather than treating total blend mass as each component amount.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | Kruse and colleagues describe the medicinal-chemistry programme leading to cagrilintide. It provides a primary source for analogue selection and design. Later combination studies require separate interpretation because two coadministered agents are not the same experimental intervention as cagrilintide alone. | Source context |
| What cannot be inferred | A development paper or combination trial does not test the catalogue lot. It cannot establish the composition, compatibility or clinical equivalence of a product sold under the CagriSema name. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Development of Cagrilintide, a Long-Acting Amylin AnaloguePrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.